NASDAQHealth CareBiotechnologySnapshot 2026-07-09
Reading SGP? Create a free portfolio, then add this holding for ongoing Reports and tracking. No credit card.
Create your account →Intact: The reason to own it still holds.
SpyGlass Pharma is developing new therapies for big health problems. It has stable management and no debt. The company beat earnings in March and aims to stabilize losses. Its partnerships could help growth.
SpyGlass Pharma is losing money with worsening earnings estimates. It missed earnings in May and faces a tough market. Revenue is zero and no clear guidance exists. The recent selloff shows investor doubts.
The market prices in ongoing losses and no revenue growth. Our view is cautious given the lack of clear forward targets and recent earnings misses.
Breaks if: net loss per share worsens beyond -$0.58 next quarter
Breaks if: management status changes to unstable
Breaks if: revenue remains at $0 next 4 quarters
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
